Cat. No.
MABL-2663
Application
FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
14-02-3
From
Recombinant Antibody
Specificity
This antibody binds human PDL1. PD-L1 is highly expressed in many human tumors. PD-L1 exerts an immune suppressive signal through binding to PD-1 and B7.1, and tumor expression of PD-L1 can mediate cancer immune evasion. Blocking this pathway, therefore provides a rationale for cancer immunotherapy.
Alternative Names
CD274; PD-L1; B7-H1; B7H1; B7 homolog 1; hPD-L1; PDCD1L1; PDCD1LG1; PDCD1 ligand 1; Programmed cell death 1 ligand 1; Programmed death ligand 1; HZ-K-Yr-13 & 14-02-3
UniProt
Q9NZQ7
Immunogen
The original antibody was generated by immunizing 2 alpacas with human PDL1 antigen in Freund's adjuvant. The peripheral blood of the alpaca was taken to generate a yeast display nanobody library and the particular clone was isolated by screening the library against human PDL1.
Application Notes
This antibody binds human PD-L1 with a binding affinity of Kd= 0.22 nM. This antibody in combination with an anti-PDL2 antibody HZ-D-Na-96-1 was used in the generation of a bispecific antibody targeting human PDL1 and PDL2 simultaneously. The resulting bispecific antibody was capable of blocking binding of PD-L2/PD-L1 to PD-1 and also block PDL1/PDL2/PD1/luc signaling pathway (WO2021197358).
Antibody First Published
Note on publication
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
